Can a Patient Take Lithium and Depakote Together?
Yes, lithium and Depakote (valproic acid) can be taken together, and combination therapy is actually more effective than valproate monotherapy for preventing relapse in bipolar disorder. The combination is commonly used in clinical practice and has been studied extensively for both acute and maintenance treatment of bipolar disorder.
Evidence for Combination Therapy
The strongest evidence comes from the BALANCE trial 1, which demonstrated that lithium plus valproate combination therapy was significantly superior to valproate monotherapy in preventing relapse (hazard ratio 0.59, p=0.0023). This large randomized trial followed 330 patients for up to 24 months and showed that combination therapy prevented more relapses than valproate alone, with benefits maintained for up to 2 years.
Additional research supports this approach:
- A pilot study found patients on lithium plus divalproex were significantly less likely to suffer relapse or recurrence (p=0.014) compared to lithium alone 2
- Initial combination therapy in acute mania showed faster response times and reduced need for additional neuroleptic medication 3
- Guidelines explicitly discuss combination therapy as a maintenance strategy, noting that many patients initially stabilized on combination therapy relapsed when switched to monotherapy 4
Safety and Pharmacokinetic Considerations
The combination is pharmacokinetically safe. A controlled study in healthy volunteers found that:
- Lithium pharmacokinetics were unchanged by valproate
- Valproate levels rose only slightly during lithium coadministration
- Adverse events did not change significantly 5
However, patients on combination therapy are more likely to experience moderate or severe side effects compared to monotherapy 2. The FDA label for Depakote does not contraindicate concurrent lithium use 6.
Monitoring Requirements
When using this combination, implement rigorous monitoring per guideline recommendations 4:
For Lithium (every 3-6 months):
- Lithium levels (therapeutic range 0.5-0.8 mmol/L for maintenance)
- Renal function (BUN, creatinine)
- Thyroid function tests
- Urinalysis
- Serum calcium
For Valproate (every 3-6 months):
- Valproate levels (therapeutic range 50-100 μg/mL)
- Liver function tests
- Complete blood counts
- Monitor for polycystic ovary disease in females
Additional monitoring:
- Weight and metabolic parameters if atypical antipsychotics are added
- Clinical assessment for signs of toxicity between scheduled labs
Clinical Decision Algorithm
Use combination therapy when:
- Monotherapy with either agent has failed to prevent relapse
- Patient has severe or treatment-resistant bipolar I disorder
- Patient was initially stabilized on combination therapy
Consider monotherapy when:
- Patient is stable on monotherapy and tolerating it well
- Minimizing polypharmacy is a priority
- Side effect burden is excessive
Special consideration: In women of childbearing potential, valproate carries the highest risk of neurodevelopmental disorders in exposed children and should be avoided during pregnancy 7. Plan switches to lithium, lamotrigine, quetiapine, olanzapine, or aripiprazole before conception.
Common Pitfalls
- Subtherapeutic dosing: Approximately one-third of patients have subtherapeutic drug levels during treatment 8. Regular therapeutic drug monitoring is essential.
- Premature discontinuation: Attempting to switch from combination to monotherapy too early often results in relapse (median time 3 months) 4
- Inadequate trial duration: Allow 6-8 weeks at adequate doses before concluding treatment failure 4
- Neglecting pregnancy planning: Valproate must be stopped during pregnancy; plan switches in advance 7